Best Myriad Genetics Q1 2026 Takeaways for Investors and Clinicians

Shoppers of genomic tests and investors alike are watching Myriad’s latest quarter , the company posted just over $200 million in Q1 revenue, with hereditary cancer strength offsetting a softer prenatal business, and management reaffirmed full-year guidance while stepping up commercial and R&D spending ahead of several launches.

Essential Takeaways

• Revenue snapshot: Q1 revenue was $200.4m, up about 2% year‑over‑year and within prior guidance, with 385,000 test results delivered and gross margin near 69% (smells of steady operational control).
• Cancer momentum: Cancer care continuum sales were $120.2m, up 4%; hereditary testing volumes rose 14% led by new myRisk panels and share gains.
• Prenatal softness: Prenatal revenue fell 15% to $41.9m, though management says volumes stabilised across the quarter and FirstGene readies a full commercial launch in H2.
• GeneSight lift: Mental health revenue (GeneSight) climbed 24% to $38.3m, helped by improved reimbursement and expanding clinician orders.
• Investment & guidance: Myriad reaffirmed FY26 revenue guidance of $860–$880m, plans about $35m in commercial investment, and flagged an adjusted EBITDA loss in Q1 with expectation of sequential improvement.

Q1 at a glance: steady top line, mixed beneath the surface

Myriad delivered roughly $200m in revenue , a modest gain that showed the business is humming but not sprinting, with a warm, steady gross margin near 69%. According to the company’s remarks, adjusted EBITDA was a small loss and adjusted EPS was negative $0.09, underscoring investment ahead of product rollouts. For investors this reads as discipline plus deliberate spending; for clinicians it means new tests are on the way without a collapse in operations.

Why hereditary cancer testing is the bright spot

The cancer care continuum led the quarter, with hereditary testing volumes up 14% year‑on‑year. Management credited an updated myRisk panel and targeted product launches , disease‑specific panels for breast, prostate, ovarian and colorectal cancers , which helped win share. Prolaris also showed mid‑single‑digit growth. If you’re a clinician, these moves signal more tailored genomic options; if you’re an investor, they point to a structural growth area likely to accelerate as a dedicated unaffected hereditary sales force ramps up.

Precise MRD and Prolaris AI: launches to watch

Myriad rolled out Precise MRD for breast cancer in March to select sites and is training customers quickly, with clinicians reporting good turnaround and sample yields. The company plans MolDX submissions later in the year and is accelerating limited launches for colorectal and renal cancers. Meanwhile, an AI‑enabled Prolaris test is slated for a June launch and is positioned as a higher‑value replacement for the current assay. These are early commercial bets that could lift pricing power if payers and clinicians adopt them broadly.

Prenatal health: the trough and the recovery plan

Prenatal revenue slipped 15% in Q1, a notable drag, though management emphasised stabilisation during the quarter and several catalysts for H2 recovery. The company has split women’s health into portfolio‑specific teams to focus on Foresight, Prequel and the upcoming FirstGene, which combines carrier, fetal single‑gene, fetal chromosome and fetal RHD results as early as eight weeks. Payer news helps too , Cigna’s April update expanded coverage for certain panels, which should ease access. For prospective parents and providers, FirstGene promises faster, broader answers but will initially be billed under existing codes until new pathways settle.

GeneSight showing tangible reimbursement progress

Mental health testing via GeneSight produced a healthy 24% revenue increase on modest volume gains, reflecting better average revenue per test and an expanding clinician base now above 39,000. Management linked the improvement to more favourable reimbursement trends, including biomarker legislation and revenue cycle optimisations. That combination of policy tailwinds and workflow fixes is exactly what biotech investors like to see , revenue durability without price gimmicks.

Spending, guidance and what to expect next

Myriad reiterated full‑year guidance of $860–$880m revenue and adjusted EBITDA between $37m and $49m, while signalling a multi‑year $35m investment in commercial capabilities and adding over 100 account executives versus last year. Management expects sequential revenue growth in Q2 and acceleration through H2 as prenatal recovers and new launches scale. Watch the cadence of hiring and the timing of reimbursement wins, because those will determine how quickly investments translate into margin improvement.

It's a small pivot and a lot of groundwork , the company is positioning for stronger, more diversified revenue in the back half of the year.

Source Reference Map

Story idea inspired by: ^[1]

Sources by paragraph:

• Paragraph 1: ^[2], ^[4]
• Paragraph 2: ^[4], ^[6]
• Paragraph 3: ^[4], ^[6]
• Paragraph 4: ^[6], ^[4]
• Paragraph 5: ^[4], ^[6]
• Paragraph 6: ^[3], ^[5]
• Paragraph 7: ^[4], ^[6]